

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6826)**

**ELECTION OF NEW SESSION OF THE BOARD  
AND  
RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

As the three-year term of office of the fifth session of the board (the “**Board**”) of directors (the “**Director(s)**”) of Shanghai Haohai Biological Technology Co., Ltd.\* (the “**Company**”) will soon expire, the sixth session of the Board shall therefore be elected and formed according to the Articles of Association of the Company and the relevant regulatory requirements. The sixth session of the Board will consist of eleven Directors, comprising four executive Directors, two non-executive Directors, four independent non-executive Directors and one staff representative Director.

A meeting of the Board was convened on 9 May 2025, at which, the Board proposed to (i) re-elect Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi, Mr. Tang Minjie, Ms. You Jie and Mr. Huang Ming as the non-independent non-executive Directors (including executive Directors and non-executive Directors but excluding independent non-executive Directors or the staff representative Director) of the sixth session of the Board; and (ii) re-elect Mr. Jiang Zhihong, Mr. Shen Hongbo, Mr. Su Zhi and Mr. Yang Yushe as independent non-executive Directors of the sixth session of the Board. The above-mentioned proposals are subject to the approval of the shareholders of the Company (the “**Shareholder(s)**”) by way of ordinary resolutions at the upcoming 2024 annual general meeting of the Company (the “**AGM**”).

In the event that the above-mentioned candidates for Directors are elected as Directors of the sixth session of the Board, their terms of office will be three years from the date of the approval by the Shareholders at the AGM, while the fifth session of the Board will continue their duties until the sixth session of the Board has been established. The Company will enter into service contracts with the Directors of the sixth session of the Board, the remuneration of whom will be determined in accordance with the Remuneration Plan of the Directors and Supervisors for 2025 to be considered and approved by the AGM and with reference to their respective duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the remuneration and appraisal committee of the Company from time to time.

The election of the staff representative Director shall be conducted by the staff of the Company democratically. The biographical details of the staff representative Director will be disclosed by way of announcement upon conclusion of the democratic election by the staff of the Company.

Mr. Zhao Lei (“**Mr. Zhao**”), an independent non-executive Director, will not stand for re-election for the sixth session of the Board due to personal reasons, and will retire from his position as a Director and as chairman of the Nomination Committee and member of the Audit Committee and Remuneration and Appraisal Committee of the Company from the date of election of the sixth session of the Board at the AGM. Mr. Zhao has confirmed that he has no disagreement with the Board and there is no matter in respect of his retirement that needs to be brought to the attention of the Shareholders and The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”). The Company and the Board would like to express its gratitude to Mr. Zhao for his diligence, fulfillment of due responsibility and contributions to the Company during his term of office.

A circular containing, among others, details of the proposals on re-election of the Directors and a notice of the AGM are published on the websites of Hong Kong Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company’s website ([www.3healthcare.com](http://www.3healthcare.com)) on 9 May 2025.

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.\***  
**Hou Yongtai**  
*Chairman*

Shanghai, the PRC, 9 May 2025

*As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.*

\* *For identification purpose only*